Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11570974 | 0.82 | NPC1 (0.35) | NPC1PKMRAB9AADRB2ADRB1 | |
| SCHEMBL30048057 | 0.81 | EPHX1 (0.44) | — | |
| SCHEMBL27260466 | 0.79 | KDM4E (0.39) | NPC1PKMRAB9AADRB2ADRB1 | |
| SCHEMBL3257035 | 0.79 | GAA (0.33) | — | |
| SCHEMBL6978891 | 0.74 | NPC1 (0.38) | NPC1PKMRAB9AADRB2ADRB1 | |
| SCHEMBL28187014 | 0.72 | — | — | |
| SCHEMBL2187338 | 0.71 | NPC1 (0.36) | NPC1PKMRAB9AMEN1KMT2A | |
| SCHEMBL25206706 | 0.69 | ALDH1A1 (0.39) | NPC1PKMRAB9AMEN1KMT2A | |
| SCHEMBL30282423 | 0.69 | KDM4C (0.38) | NPC1PKMRAB9AMEN1KMT2A | |
| SCHEMBL11307278 | 0.69 | MAPT (0.39) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4143179-B1 | AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-10-22 | — | — | EP | disclosed |
| US-20230174514-A1 | AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-06-08 | — | — | US | disclosed |
| EP-4143179-A1 | AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2023-03-08 | — | — | EP | disclosed |
| CN-115551841-A | Azetidin-3-ylcarbinol derivatives as modulators of the CCR6 receptor | 爱杜西亚药品有限公司 | 2022-12-30 | — | — | CN | disclosed |
| US-9873680-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873680-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| WO-2016033243-A9 | ANTIRETROVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
| US-20160083368-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-03-24 | — | — | US | disclosed |
| US-20160083368-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-03-24 | — | — | US | disclosed |
| US-8883778-B2 | Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| EP-2448928-B1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS INC (US) | 2014-08-13 | — | — | EP | disclosed |
| US-20120232050-A1 | Cyclic Inhibitors of 11 beta-Hydroxysteroid Dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2012-09-13 | — | — | US | disclosed |
| EP-2448928-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Vitae Pharmaceuticals, Inc. (US) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011002910-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083368-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, G6PD | NPC1 9/4885PKM 2289/4885RAB9A 290/4885 |
| US-20120232050-A1 | Cyclic Inhibitors of 11 beta-Hydroxysteroid Dehydrogenase 1 | HSD11B1, HSD3B1, HSD11B2 | NPC1 799/4885PKM 1753/4885RAB9A 3494/4885 |
| US-20230174514-A1 | AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS | CCR6, CCR1, CCR3 | NPC1 119/4885PKM 4224/4885RAB9A 2421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.